- Home
- IPA vs APLM Comparison
IPA vs APLM Comparison
Compare IPA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- APLM
- Stock Information
- Founded
- IPA 1983
- APLM 2016
- Country
- IPA Canada
- APLM United States
- Employees
- IPA N/A
- APLM N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- IPA Health Care
- APLM Finance
- Exchange
- IPA Nasdaq
- APLM Nasdaq
- Market Cap
- IPA 15.3M
- APLM 12.3M
- IPO Year
- IPA 2017
- APLM N/A
- Fundamental
- Price
- IPA $0.53
- APLM $9.56
- Analyst Decision
- IPA Strong Buy
- APLM Strong Buy
- Analyst Count
- IPA 2
- APLM 2
- Target Price
- IPA $5.00
- APLM $425.00
- AVG Volume (30 Days)
- IPA 422.7K
- APLM 36.2K
- Earning Date
- IPA 03-13-2025
- APLM 02-15-2025
- Dividend Yield
- IPA N/A
- APLM N/A
- EPS Growth
- IPA N/A
- APLM N/A
- EPS
- IPA N/A
- APLM N/A
- Revenue
- IPA $17,272,336.00
- APLM $2,101,000.00
- Revenue This Year
- IPA $1.88
- APLM N/A
- Revenue Next Year
- IPA $9.90
- APLM N/A
- P/E Ratio
- IPA N/A
- APLM N/A
- Revenue Growth
- IPA 6.36
- APLM 70.54
- 52 Week Low
- IPA $0.33
- APLM $6.50
- 52 Week High
- IPA $2.60
- APLM $91.00
- Technical
- Relative Strength Index (RSI)
- IPA 58.77
- APLM 46.48
- Support Level
- IPA $0.43
- APLM $9.50
- Resistance Level
- IPA $0.59
- APLM $10.67
- Average True Range (ATR)
- IPA 0.07
- APLM 0.92
- MACD
- IPA 0.01
- APLM -0.04
- Stochastic Oscillator
- IPA 71.48
- APLM 13.17
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.